LuciElace 345 mg (Elacestrant) 345mg

LuciElace 345 mg is a hormone therapy used to treat estrogen receptor-positive breast cancer. It is specifically indicated for patients with advanced or metastatic breast cancer who have experienced disease progression after previous endocrine therapy.

• Estrogen receptor-positive breast cancer: Treats advanced or metastatic breast cancer in postmenopausal women or adult men with ESR1 mutations.
• HER2-negative breast cancer: Effective in patients whose cancer does not express the HER2 protein.
• ESR1-mutated breast cancer: Targets cancer with specific mutations in the estrogen receptor gene.

• Elacestrant works by binding to estrogen receptors and promoting their degradation. This action inhibits the growth of estrogen-driven tumors by preventing estrogen from stimulating cancer cell proliferation. It is particularly effective in patients with ESR1 mutations, which are common in advanced breast cancer.

LuciElace 345 mg may cause various side effects, ranging from common to serious.

Common Side Effects

• Nausea: Feeling sick to the stomach.
• Fatigue: A feeling of tiredness or weakness.
• Vomiting: Expelling stomach contents through the mouth.
• Decreased appetite: A reduced desire to eat.
• Constipation: Difficulty passing stools.
• Hair loss: Thinning or loss of hair.
• Diarrhea: Frequent, loose, or watery bowel movements.
• Headache: Pain in the head.

Serious or Rare Side Effects

• Liver toxicity: Damage to the liver, which can cause jaundice or abnormal liver function tests.
• Bone fractures: Increased risk of bone breaks due to the medication's effects on bone density.
• Allergic reactions: Severe allergic responses, including rash, itching, or difficulty breathing.

LuciElace 345 mg should be used with caution and under medical supervision. Important precautions include:

• Pregnancy: Avoid use during pregnancy due to potential harm to the fetus.
• Breastfeeding: Do not use while breastfeeding.
• Hepatic impairment: Adjust dosage for patients with moderate hepatic impairment.
• Drug interactions: Avoid concurrent use with strong CYP3A inducers or inhibitors.
• Monitoring: Regularly monitor liver function and bone health during treatment.
• Storage: Store at 20℃ to 25℃: Keep in a dry place and out of reach of children.

LuciElace 345 mg may interact with other medications, which can affect its efficacy or increase the risk of side effects.

Major Interactions (Avoid)

• Strong CYP3A inducers: Such as rifampin, which can decrease elacestrant levels.
• Strong CYP3A inhibitors: Such as ketoconazole, which can increase elacestrant levels.
• Hormonal therapies: Other estrogen receptor modulators or antagonists.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A inducers: Such as efavirenz, which may reduce elacestrant effectiveness.
• Moderate CYP3A inhibitors: Such as fluconazole, which may increase elacestrant levels.
• Herbal products: Such as St. John's Wort, which can affect drug metabolism.